TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34606560
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (540 mg GLA per day)
Study: 35438442
Drug: eHealth Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Study: 33439215
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of risk factors (high SES, low PRS)
Study: 33439215
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of risk factors (high PRS, parental history)
Study: 36625789
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate
Study: 33567780
Drug: Spirulina maxima
Normalized name: SPIRULINA MAXIMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina maxima intake (5 g/day)
Study: 32107871
Drug: Home titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home titration using an APAP device for three days
Study: 32107871
Drug: Laboratory attended
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory attended APAP titration
Study: 32370596
Drug: Antibody 1
Normalized name: Blood group antibody 1123K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody 1
Study: 32370596
Drug: Antibody 2
Normalized name: Monoclonal Antibody 2C4
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibody 2
Study: 32370596
Drug: Antibody 3
Normalized name: MONOCLONAL ANTIBODY 3F8
DrugBank: Anti-GD2 monoclonal antibody 3F8 (DB15388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody 3
Study: 32370596
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three antibodies
Study: 39527516
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) intervention
Study: 35508008
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide + placebo
Study: 35843914
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg during induction)
Study: 35843914
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (1.5 gr/hr as continuous intravenous infusion after intubation)
Study: 35843914
Drug: Fentanyl (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (bolus doses during surgery)
Study: 33407599
Drug: Whole tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tomato food supplement (WTFS)
Study: 35713160
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus 20 g vitamin C once daily (1-10 days) and 500 mg twice daily (11-100 days)
Study: 35690931
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HiRIT and medication
Study: 32085539
Drug: Monthly budget
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly budget
Study: 37004331
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (OAP)
Study: 35247794
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (OAP/OAP)
Study: 35247794
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (OAP/PP)
Study: 32448257
Drug: 800mcg sublingual
Normalized name: ABSTRAL 800mcg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mcg sublingual misoprostol given only to women with 350-500 ml postpartum blood loss (secondary prevention)
Study: 33411992
Drug: Prefilled syringe
Normalized name: Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefilled syringe (fremanezumab 225 mg)
Study: 36326117
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of RAS inhibitors
Study: 33872601
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone injected into gluteal muscle
Study: 33872601
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone injected into masseter muscle
Study: 35017010
Drug: Intravenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GLP-1 infusion (2.5 pmol/kg/min)
Study: 33939911
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (group 3)
Study: 34391744
Drug: Transcatheter mitral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter mitral valve repair (TMVr) plus guideline-directed medical therapy (GDMT)
Study: 35852098
Drug: Venetoclax in
Normalized name: Product containing venetoclax in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax in combination with oral azacitidine (CC‐486) as maintenance therapy
Study: 32791894
Drug: Olanzapine/samidorphan combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/samidorphan combination
Study: 33009729
Drug: Antivirals or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivirals or treatment of complications (specifics not provided)
Study: 35577631
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg +/‐ CpG1018
Study: 35577631
Drug: 3 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg alone
Study: 33298104
Drug: Diluted maple
Normalized name: coast maple pollen extract
DrugBank: Acer macrophyllum pollen (DB10734)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted maple syrup (MS)
Study: 33304282
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg THC
Study: 33517882
Drug: Additional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional daily physical therapy focused on mobility (n=99)
Study: 33517882
Drug: Additional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional daily physical therapy focused on mobility
Study: 32956615
Drug: Supportive care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care, intravenous immunoglobulin, methylprednisolone, biological therapies (IL-1 antagonists, IL-6 receptor blockers, anti-TNF agents)
Study: 32956615
Drug: IL-1 antagonists
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 antagonists (e.g., anakinra), IL-6 receptor blockers (e.g., tocilizumab), anti-TNF agents (e.g., infliximab)
Study: 32956615
Drug: New PIMS-TS
Approvals — FDA: no, EMA: no, PMDA: no
Description: New PIMS-TS specific treatment groups
Study: 32484940
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 200 μg/d
Study: 32484940
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) high doses (≥1000 μg BID)
Study: 32484940
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) high doses (≥1500 μg BID)
Study: 36107516
Drug: Dance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance therapy using telerehabilitation (n = 9)
Study: 36107516
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (n = 8)
Study: 34363617
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg IV plus diphenhydramine 25 mg IV
Study: 34515993
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy
Study: 34642762
Drug: Free amino
Normalized name: FREE AMINO ACID DIET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free amino acids (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Study: 34642762
Drug: Intact milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact milk protein (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Study: 36253339
Drug: Infant massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant massage (5 weeks, daily for at least 10 minutes)
Study: 36872873
Drug: Standard-of-care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapy
Study: 38445295
Drug: Berotralstat 150
Normalized name: berotralstat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotralstat 150 mg
Study: 33098856
Drug: Berotralstat 110
Normalized name: berotralstat 110 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotralstat 110 mg
Study: 33220855
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 (standard-dose)
Study: 33220855
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 (single standard dose)
Study: 34816288
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (early-PN)
Study: 32260466
Drug: Schisandra Chinensis
Normalized name: SCHISANDRA CHINENSIS SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schisandra Chinensis extract (1000 mg per day)
Study: 33106171
Drug: Melatonin capsules
Normalized name: melatonin Oral Capsule
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin capsules at a dose of 50 mg daily for a period of seven days
Study: 33106171
Drug: Melatonin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin and standard treatment
Study: 33106171
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and standard treatment
Study: 33709288
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy
Study: 36458679
Drug: Desidustat 50
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat 50 mg orally in a fed state
Study: 34494517
Drug: Ultra-fast track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-fast track cardiac anaesthesia (Group D) with dexmedetomidine at 1 ?g/kg/hour and sufentanil for analgesia
Study: 35148706
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) counseling
Study: 35833334
Drug: Erythropoietin (ESA)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (ESA) treatment
Study: 37400931
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron treatment
Study: 35662232
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg/d for 12 weeks
Study: 38325518
Drug: Individual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual and Group Supportive Therapy (IGST)
Study: 35360477
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic nursing
Study: 35572982
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy alone for 4 months
Study: 34587371
Drug: Liposomal cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal cyclosporine A for inhalation (L‐CsA‐i) administered twice daily via nebulizer for 2 years
Study: 34587371
Drug: Liposomal cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal cyclosporine A for inhalation (L‐CsA‐i) administered to SLT recipients
Study: 35653577
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac 30 mg
Study: 33351126
Drug: Polyvalent immunoglobulin
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent immunoglobulin preparation
Study: 33351126
Drug: Pneumolysin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumolysin treatment
Study: 34185723
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 0.5% ropivacaine (low-volume STB)
Study: 34185723
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL 0.5% ropivacaine (standard-volume STB)
Study: 37079569
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies
Study: 32131077
Drug: Smartphone overdependence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone overdependence prevention program (8 sessions, twice a week)
Study: 33788599
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT); n=46, 12 weekly 90-min group sessions.
Study: 32966971
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro plus glargine
Study: 32576561
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with exenatide (2 mg/week) and pioglitazone (30 mg/day)
Study: 32576561
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin (glargine with aspart)
Study: 36056908
Drug: Ultrasound-guided capsular
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided capsular injection of dexamethasone (DEX) and lidocaine
Study: 32104059
Drug: Intravenous steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous steroids
Study: 32838647
Drug: standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose regimen (tenofovir disoproxil 200 mg, efavirenz 600 mg and lamivudine)
Study: 32838647
Drug: lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: lower dose regimen (tenofovir disoproxil 200 mg, efavirenz 400 mg and lamivudine)
Study: 33217193
Drug: Sorafenib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib therapy
Study: 33781142
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg
Study: 32876962
Drug: Low frequent
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequent high dosage IVIg treatment
Study: 34927594
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) (control group)
Study: 35863457
Drug: Oteseconazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oteseconazole (600 mg on day 1 and 450 mg on day 2)
Study: 35863457
Drug: Fluconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (3 sequential 150-mg doses every 72 hours)
Study: 35863457
Drug: Oteseconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oteseconazole (150 mg weekly for 11 weeks)
Study: 35863457
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mg weekly for 11 weeks)
Study: 33473019
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: 36654288
Drug: Bumetanide 0.5
Normalized name: bumetanide 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.5 mg
Study: 35193441
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction (DR) of adalimumab
Study: 35193441
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction (DR) of ustekinumab
Study: 35193441
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction (DR) of etanercept
Study: 35945733
Drug: Acupuncture, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, administered twice a week for 6 weeks (total of 12 sessions) on 9 defined acupuncture points.
Study: 35945733
Drug: Thread embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thread embedding acupuncture (TEA), administered once a week for 6 weeks (total of 6 sessions) on 14 defined knee areas.
Study: 33230077
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) bi-weekly for 6 weeks
Study: 35238476
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous ornithine phenylacetate (OP)
Study: 33818978
Drug: Weekly injection
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injection (more effective)
Study: 33818978
Drug: Weekly injection
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injection with decoy
Study: 33818978
Drug: Every-three-month injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every-three-month injection with decoy
Study: 32600400
Drug: Internet-based psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based psychodynamic treatment (IPDT)
Study: 39445776
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg
Study: 39141364
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg
Study: 34545652
Drug: Controlled-release dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release dinoprostone vaginal delivery system (PROPESS)
Study: 32246662
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin ointment
Study: 33188584
Drug: 1% DCI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% DCI, 0.25% DCI, vehiculum without active agent
Study: 33037320
Drug: H4:IC31 (subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: H4:IC31 (subunit vaccine containing Ag85B and TB10.4)
Study: 33037320
Drug: BCG (live
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (live attenuated vaccine)
Study: 35674488
Drug: EDS-FLU 186
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-FLU 186 μg
Study: 35674488
Drug: EDS-FLU 372
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-FLU 372 μg (prior ESS)
Study: 35674488
Drug: EDS-FLU 186
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-FLU 186 μg (unoperated)
Study: 35674488
Drug: EDS-FLU 372
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-FLU 372 μg (unoperated)
Study: 34418958
Drug: Receiving the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving the results of a SARS-CoV-2 antibody test
Study: 33370007
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (perceived)
Study: 33370007
Drug: Low-dose caffeine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose caffeine (perceived)
Study: 33689730
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at 6 L/min for 6‐12 hours
Study: 32099328
Drug: Ovidrel® (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovidrel® (reference drug)
Study: 32099328
Drug: LZM003 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: LZM003 (test drug)
Study: 36273216
Drug: Phenytoin 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 10% cream
Study: 34667404
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus conventional therapy
Study: 39181597
Drug: Semaglutide 2·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2·4 mg
Study: 33556413
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 19)
Study: 33139710
Drug: Nimodipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (60 mg single oral dose)
Study: 33980290
Drug: Gratitude journal
Normalized name: Journavx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gratitude journal intervention (logging 5 things they felt grateful for daily for 2 weeks)
Study: 33980290
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily self-evaluations only)
Study: 33909357
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (50 mg once daily)
Study: 36571569
Drug: ticagrelor/aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor/aspirin
Study: 36571569
Drug: clopidogrel/aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel/aspirin
Study: 34432984
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (ICBT) for tinnitus
Study: 39208825
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard therapy
Study: 32527346
Drug: Xuebijing 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing 100 mL group
Study: 34579741
Drug: Anisodamine (0.1-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodamine (0.1-0.5 mg/kg/hour)